Silexion Therapeutics Ltd. (SLXNW)
Silexion Therapeutics Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Jerusalem, TA, IL. The stock last traded at $0.01, up 30.26% on the session, giving a market capitalisation of $5,554. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -0.27 implies it has historically moved less than the broad market.
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Silexion Therapeutics Ltd. is most often compared with the following Healthcare names: